DANBURY, Conn., Dec. 18, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2013.

Portfolio highlights since last fiscal quarter:
  • Executed long-term commercial supply agreement with BD (Becton, Dickinson and Company) for worldwide exclusive rights to the ultra-portable and proprietary Uniject™ device for the delivery of liquid glucagon to treat severe hypoglycemia.
  • Manufactured engineering batch of BIOD-961 glucagon formulation for the EZMix™ auto-reconstitution device in preparation for initiation of IND-enabling toxicology studies.
  • Presented preclinical glucagon formulation data at Diabetes Technology Meeting demonstrating commercially viable pharmacokinetic and pharmacodynamic profiles comparable to glucagon products marketed by Eli Lilly and Novo Nordisk.
  • Reported positive top-line data from Phase 2 clinical trial of ultra-rapid-acting insulin candidate BIOD-123 and requested meeting with FDA.
  • Improved stability of analog-based ultra-rapid-acting insulin formulations.
  • Initiated Phase 1 clinical trial of concentrated ultra-rapid-acting insulin candidate BIOD-531.

Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "I am pleased with the progress we have made across our rapidly progressing portfolio of innovative therapies for the treatment of diabetes. We look forward to delivering on several key milestones in 2014 including reporting top-line data from the BIOD-531 Phase 1 trial in the next calendar quarter, identifying analog-based ultra-rapid-acting insulin candidates and initiating pivotal trials on our glucagon program in the second half of 2014."

Fourth Quarter Financial Results

Biodel reported a net loss for the three months ended September 30, 2013 of $0.8 million, or $0.04 per share of common stock, compared to a net loss of $5.9 million, or $0.42 per share of common stock, for the same period in the prior year.

Research and development expenses were $2.9 million for the three months ended September 30, 2013, compared to $4.6 million for the same period in the prior year. The decrease in research and development expenses was primarily attributable to the completion of our Phase 2 clinical trial of BIOD-123.

General and administrative expenses were $1.7 million for the three months ended September 30, 2013, compared to $1.2 million for the same period in the prior year.

Expenses for the three months ended September 30, 2013 and 2012 included costs of $0.3 million each in stock-based compensation expense related to options and restricted stock units granted to employees and our non-employee directors.

Biodel did not recognize any revenue during the three months ended September 30, 2013 or 2012.

At September 30, 2013, Biodel had cash and cash equivalents of $39.8 million and 21.1 million shares of common stock outstanding.

Conference Call and Webcast Information

Biodel's senior management will host a conference call on December 18, 2013 beginning at 5:00 p.m. Eastern Time to discuss these results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing +1 (877) 303-8028 (United States) or +1 (760) 536-5167 (international). To access the call by live audio webcast, please log on to the investor section of the company's website at www.biodel.com. An archived version of the audio webcast will be available on Biodel's website. Interested parties may also access an audio replay by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference ID number 13631899.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at  www.biodel.com.
Biodel Inc.
(A Development Stage Company)
Balance Sheets
(In thousands, except share and per share amounts)
  September 30,
  2012 2013
Cash and cash equivalents  $ 39,050  $ 39,781
Restricted cash 60 -
Taxes receivable 34 6
Grant receivable 88 26
Other receivable 9 -
Prepaid and other assets 295 264
Total current assets 39,536 40,077
Property and equipment, net 1,552 1,031
Intellectual property, net 46 43
Long term other assets -
Total assets  $ 41,134  $ 41,151
Accounts payable  $ 285  $ 246
Accrued expenses:    
Clinical trial expenses 488 181
Payroll and related 1,248 1,139
Accounting and legal fees 244 226
Severance 141 255
Other 273 319
Income taxes payable 101 75
Total current liabilities 2,780 2,441
Common stock warrant liability 7,338 6,121
Severance payable, long term portion 26
Total liabilities 10,118 8,588
Stockholders' equity:    
Convertible preferred stock, $.01 par value; 50,000,000 shares authorized, 5,419,551 and 1,950,000 issued and outstanding 54 19
Common stock, $.01 par value; 62,500,000 shares authorized; 14,174,545 and 21,070,824 issued and outstanding 142 211
Additional paid-in capital 226,913 247,761
Deficit accumulated during the development stage (196,093) (215,428)
Total stockholders' equity 31,016 32,563
Total liabilities and stockholders' equity  $ 41,134  $ 41,151
Biodel Inc.
(A Development Stage Company)
Statements of Operations
(In thousands, except share and per share amounts)
  Year Ended September 30, (Inception)
  2011 2012 2013 2013
Revenue $ — $ — $ — $ —
Operating expenses:        
Research and development 13,597 12,315 14,296 155,400
Government grants (88) (546) (634)
General and administrative 9,625 7,072 6,843 72,201
Total operating expenses 23,222 19,299 20,593 226,967
Other (income) and expense:        
Interest and other income (60) (80) (56) (5,702)
Interest expense 78
Adjustments to fair value of common stock warrant liability (12,611) 1,510 (1,217) (11,064)
Loss on settlement of debt 627
Loss before tax provision (benefit) (10,551) (20,729) (19,320) (210,906)
Tax provision (benefit) 41 18 15 (538)
Net loss (10,592) (20,747) (19,335) (210,368)
Charge for accretion of beneficial conversion rights (603)
Deemed dividend — warrants (4,457)
Net loss applicable to common stockholders  $ (10,592)  $ (20,747)  $ (19,335)  $ (215,428)
Net loss per share — basic and diluted*  $ (1.36)  $ (1.91)  $ (1.24)  
Weighted average shares outstanding — basic and diluted* 7,788,741 10,882,688 15,650,538  
* Restated for a one for four (1:4) reverse stock split effective on June 11, 2012.

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with type 1 and type 2 diabetes and our glucagon presentation that is intended to treat patients experiencing severe hypoglycemia; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin or a stable glucagon presentation; the success of our formulation development work with insulin analog-based formulations of a proprietary injectable insulin and a stable glucagon presentation; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject ® ), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended June 30, 2013. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

CONTACT: John Graziano, +1 (646) 378 2942